Testing effectiveness (Phase 2)Study completedNCT00389441What this trial is testingStudy Of AG-013736 In Patients With 131I-Refractory Thyroid CancerWho this might be right forThyroid Neoplasms Pfizer 52
Not applicableApproved For MarketingNCT03533361What this trial is testingExpanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in BrazilWho this might be right forThyroid Cancer Eisai Inc.
Large-scale testing (Phase 3)Study completedNCT02966093What this trial is testingA Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in ChinaWho this might be right forDifferentiated Thyroid Cancer (DTC) Eisai Co., Ltd. 151
Not applicableStudy completedNCT00970359What this trial is testingReacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244Who this might be right forThyroid Cancer Memorial Sloan Kettering Cancer Center 24
Testing effectiveness (Phase 2)Looking for participantsNCT06007924What this trial is testingAvutometinib and Defactinib in People With Thyroid CancerWho this might be right forThyroid Cancer Memorial Sloan Kettering Cancer Center 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04061980What this trial is testingEncorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid CancerWho this might be right forBRAF NP_004324.2:p.V600MBRAF V600E Mutation PresentMetastatic Thyroid Gland Carcinoma+4 more Providence Health & Services 24
Early research (Phase 1)Ended earlyNCT03420963What this trial is testingDonor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid TumorsWho this might be right forRecurrent Cutaneous MelanomaRecurrent Lip and Oral Cavity CarcinomaRecurrent Malignant Endocrine Neoplasm+25 more M.D. Anderson Cancer Center 12
Large-scale testing (Phase 3)Ended earlyNCT03602495What this trial is testingDonafenib in Patients With Radioiodine-refractory Differentiated Thyroid CancerWho this might be right forDifferentiated Thyroid Cancer Suzhou Zelgen Biopharmaceuticals Co.,Ltd 204
Early research (Phase 1)Ended earlyNCT00002947What this trial is testingIndium In 111 Pentetreotide in Treating Patients With Refractory CancerWho this might be right forBrain and Central Nervous System TumorsChildhood Langerhans Cell HistiocytosisGastrointestinal Carcinoid Tumor+9 more Yale University 35
Not applicableLooking for participantsNCT05733013What this trial is testingCollect Information About the Use of Redifferentiating Medications as a Standard Treatment for Thyroid CancerWho this might be right forThyroid CancerThyroidRefractory Thyroid Cancer Memorial Sloan Kettering Cancer Center 100
Not applicableStudy completedNCT01534897What this trial is testingRe-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436Who this might be right forPapillary Thyroid Carcinoma Massachusetts General Hospital 10
Early research (Phase 1)Study completedNCT01638533What this trial is testingRomidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionWho this might be right forGliomaHematopoietic and Lymphoid Cell NeoplasmLymphoma+47 more National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Study completedNCT03246958What this trial is testingNivolumab Plus Ipilimumab in Thyroid CancerWho this might be right forThyroid Cancer Dana-Farber Cancer Institute 53
Testing effectiveness (Phase 2)Study completedNCT00559949What this trial is testingSelumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive IodineWho this might be right forRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Papillary CarcinomaStage II Thyroid Gland Papillary Carcinoma+2 more National Cancer Institute (NCI) 39
Early research (Phase 1)Active Not RecruitingNCT01947023What this trial is testingDabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by SurgeryWho this might be right forMetastatic Thyroid Gland CarcinomaUnresectable Thyroid Gland Carcinoma National Cancer Institute (NCI) 23
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052What this trial is testingStudy of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid CancerWho this might be right forDifferentiated Thyroid Cancer (DTC) Novartis Pharmaceuticals 153